Yahoo
NasdaqGS - Delayed Quote USD

Ascendis Pharma A/S (ASND)

270.56 -0.56 (-0.21%)
At close: September 4 at 4:00:00 PM EDT
271.00 +0.44 (+0.16%)
After hours: September 4 at 7:39:57 PM EDT
Trade ASND on Coinbase
Chart Range Bar
Loading chart for ASND
  • Previous Close 271.12
  • Open 266.77
  • Bid 248.42 x 200
  • Ask 288.09 x 200
  • Day's Range 265.22 - 271.14
  • 52 Week Range 186.05 - 282.15
  • Volume 719,532
  • Avg. Volume 665,274
  • Market Cap (intraday) 17.747B
  • Beta (5Y Monthly) --
  • PE Ratio (TTM) 20.92
  • EPS (TTM) 12.93
  • Earnings Date (est.) --
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 314.66

Ascendis Pharma A/S, operates as a biopharmaceutical company that focuses on developing TransCon-based therapies for unmet medical needs in Europe, the United States, and internationally. The company offers SKYTROFA for treating pediatric patients with growth hormone deficiency; and YORVIPATH, a once-daily subcutaneous injection for the treatment of adults with chronic hypoparathyroidism. It is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is based in Hellerup, Denmark.

ascendispharma.com

1,189

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview

Trailing total returns as of 9/4/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ASND
26.88%
S&P 500 (^GSPC)
12.75%

1-Year Return

ASND
36.56%
S&P 500 (^GSPC)
18.71%

3-Year Return

ASND
175.32%
S&P 500 (^GSPC)
70.93%

5-Year Return

ASND
62.01%
S&P 500 (^GSPC)
70.18%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 246.6M
Earnings 629.34M
Profit Margin 255.21%

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
200M
400M
600M
0.0%
100.0%
200.0%

Analyst Insights

View More

Analyst Price Targets

270.16
314.66 Average
270.56 Current
362.64 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 9/2/2026
Analyst Oppenheimer
Rating Action Maintains
Rating Outperform
Price Action Raises
Price Target 304 -> 312

Statistics

View More

Valuation Measures

Annual
As of 9/2/2026
  • Market Cap

    17.53B

  • Enterprise Value

    17.11B

  • Trailing P/E

    20.56

  • Forward P/E

    23.75

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    13.92

  • Price/Book (mrq)

    10.51

  • Enterprise Value/Revenue

    14.10

  • Enterprise Value/EBITDA

    77.44

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    70.85%

  • Return on Assets (ttm)

    9.58%

  • Return on Equity (ttm)

    118.78%

  • Revenue (ttm)

    1.05B

  • Net Income Avi to Common (ttm)

    741.76M

  • Diluted EPS (ttm)

    12.93

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    812.26M

  • Total Debt/Equity (mrq)

    31.33%

  • Levered Free Cash Flow (ttm)

    12.77M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

270.56 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: